Caitlin E Hoffman1,2, Ayako Ochi3, Orlando Carter Snead3, Elysa Widjaja4, Cynthia Hawkins5, Martin Tisdal6, James T Rutka6. 1. Division of Pediatric Neurosurgery, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. ceh2003@med.cornell.edu. 2. Department of Neurological Surgery, Weill Cornell Medical College, New York, NY, USA. ceh2003@med.cornell.edu. 3. Division of Neurology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. 4. Division of Diagnostic Imaging, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. 5. Division of Neuropathology, Hospital for Sick Children, Toronto, ON, Canada. 6. Division of Pediatric Neurosurgery, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Abstract
PURPOSE: Rasmussen's encephalitis (RE) is a hemispheric inflammatory disorder resulting in progressive epilepsy, hemiparesis, and cognitive decline. Controversy surrounds the most effective timing of surgery with respect to language dominance, functional status, and seizure outcome. We describe our experience with RE to inform treatment decisions. METHODS: A retrospective chart review was performed in children diagnosed with RE from 1983 to 2012. RESULTS: Thirteen consecutive cases were identified: six males and seven females with a mean age of 10.6 years (range 5-18). Nine patients received immunotherapy, with transient benefit in three, treatment-associated complications in two, and no difference in their mean time to treatment (5.38 vs 6.37 years p = 0.74) or long-term outcome. Mean follow-up was 5.6 years (range 0.58-12.25). There was no difference in outcome based on pre-operative duration of seizures. At last follow-up, 63 % of surgically treated patients achieved seizure freedom, 100 % had improved seizure control, 90 % had improved cognitive function, 36 % stopped medication, and 63 % tapered medication. Language improved in 83 % of patients with dominant disease. These findings were not associated with age at treatment. All surgical patients were ambulatory at last follow-up. CONCLUSIONS: Hemispherotomy achieves good seizure control with cognitive improvement and ambulatory status post-operatively. Time to surgery and dominant disease were not associated with outcome, suggesting that hemispherotomy can be offered early or late, with expectations of good seizure control and functional outcome, even with dominant disease.
PURPOSE: Rasmussen's encephalitis (RE) is a hemispheric inflammatory disorder resulting in progressive epilepsy, hemiparesis, and cognitive decline. Controversy surrounds the most effective timing of surgery with respect to language dominance, functional status, and seizure outcome. We describe our experience with RE to inform treatment decisions. METHODS: A retrospective chart review was performed in children diagnosed with RE from 1983 to 2012. RESULTS: Thirteen consecutive cases were identified: six males and seven females with a mean age of 10.6 years (range 5-18). Nine patients received immunotherapy, with transient benefit in three, treatment-associated complications in two, and no difference in their mean time to treatment (5.38 vs 6.37 years p = 0.74) or long-term outcome. Mean follow-up was 5.6 years (range 0.58-12.25). There was no difference in outcome based on pre-operative duration of seizures. At last follow-up, 63 % of surgically treated patients achieved seizure freedom, 100 % had improved seizure control, 90 % had improved cognitive function, 36 % stopped medication, and 63 % tapered medication. Language improved in 83 % of patients with dominant disease. These findings were not associated with age at treatment. All surgical patients were ambulatory at last follow-up. CONCLUSIONS: Hemispherotomy achieves good seizure control with cognitive improvement and ambulatory status post-operatively. Time to surgery and dominant disease were not associated with outcome, suggesting that hemispherotomy can be offered early or late, with expectations of good seizure control and functional outcome, even with dominant disease.
Entities:
Keywords:
Hemispherotomy; Immunotherapy; Intractable epilepsy; MEG
Authors: L Chiapparini; T Granata; L Farina; E Ciceri; A Erbetta; F Ragona; E Freri; L Fusco; G Gobbi; G Capovilla; L Tassi; L Giordano; M Viri; B Dalla Bernardina; R Spreafico; M Savoiardo Journal: Neuroradiology Date: 2003-02-12 Impact factor: 2.804
Authors: Andrew J Durnford; William Rodgers; Fenella J Kirkham; Mark A Mullee; Andrea Whitney; Martin Prevett; Lucy Kinton; Matthew Harris; William P Gray Journal: Seizure Date: 2011-09-14 Impact factor: 3.184
Authors: Cristina V Torres; Aria Fallah; George M Ibrahim; Samuel Cheshier; Hiroshi Otsubo; Ayako Ochi; Sylvester Chuang; O Carter Snead; Stephanie Holowka; James T Rutka Journal: J Neurosurg Pediatr Date: 2011-12 Impact factor: 2.375
Authors: D Boatman; J Freeman; E Vining; M Pulsifer; D Miglioretti; R Minahan; B Carson; J Brandt; G McKhann Journal: Ann Neurol Date: 1999-10 Impact factor: 10.422
Authors: Y M Hart; M Cortez; F Andermann; P Hwang; D R Fish; O Dulac; K Silver; N Fejerman; H Cross; A Sherwin Journal: Neurology Date: 1994-06 Impact factor: 9.910
Authors: Christian G Bien; Henning Tiemeier; Robert Sassen; Stefan Kuczaty; Horst Urbach; Marec von Lehe; Albert J Becker; Thomas Bast; Peter Herkenrath; Michael Karenfort; Bernd Kruse; Gerhard Kurlemann; Sabine Rona; Susanne Schubert-Bast; Silvia Vieker; Stefan Vlaho; Bernd Wilken; Christian E Elger Journal: Epilepsia Date: 2012-12-06 Impact factor: 5.864